Earlier in February, the New Delhi bench of the National Company Law Tribunal (NCLT) approved the amalgamation of Shree Jee ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

Earlier this week, German manufacturer Boehringer Ingelheim’s patent to manufacture Empagliflozin, a medication to treat type 2 diabetes mellitus, expired in India. Empagliflozin is sold under ...

This price reduction has been made possible due to the launch of generic versions of empagliflozin by drugmakers Mankind, Alkem, and Glenmark. Mankind Pharma, in a statement, announced that its ...

That’s why we have introduced empagliflozin at an affordable price, making it accessible to millions of Indian diabetes patients," said Rajeev Juneja, Vice Chairman & MD, Mankind Pharma.

Mankind Pharma has launched its affordable generic version empagliflozin in India for diabetes following its patent expiration. The launch follows patent expiration of empagliflozin sold by German ...

It comes as drugmakers Mankind, Alkem, Glenmark launched generic versions of empagliflozin. In a statement, Mankind Pharma said that its Empagliflozin will now be sold at Rs 5.49 per tablet for the 10 ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney risks, holds significant promise for volume growth as it becomes more ...